Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Oxidized lipids are known to play a key role in inflaming blood vessels and hardening arteries, which causes diseases like atherosclerosis. A new study at UCLA demonstrates that they may also contribute to pulmonary hypertension, a serious lung disease that narrows the small blood vessels in the lungs.
Patients with pulmonary hypertension have reduced right ventricular strain and more dyssynchronous ventricles than healthy individuals, show results of a three-dimensional speckle tracking study.
Researchers from the Netherlands have identified three baseline variables that may qualify as treatment goals in children with pulmonary arterial hypertension.
Elderly men and patients with low baseline systolic blood pressure are among those at a particularly high risk of death from pulmonary arterial hypertension associated with systemic sclerosis, a US study has found.
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival (PFS).
Patients with newly diagnosed pulmonary arterial hypertension have a substantial burden of disease, with more than half hospitalised during the first 3 years post-diagnosis, research shows.
An updated CHEST guideline for treating pulmonary arterial hypertension provides some evidence-based recommendations but also highlights many evidence gaps.
Exercise haemodynamic variables, measured shortly after diagnosis, correlate with exercise capacity and predict survival in patients with pulmonary arterial hypertension, study findings indicate.
Pulmonary arterial hypertension affects just over 3% of individuals with congenital heart disease, reveal nationwide data from the Netherlands.
N-terminal pro-brain natriuretic peptide remains a valid predictor in patients with pulmonary arterial hypertension who have concomitant renal dysfunction, say researchers.
Researchers have published a protocol for use of inotropic agents during initiation of epoprostenol therapy in patients with severe pulmonary arterial hypertension.
Researchers have identified clinical features that could help predict which patients with systemic sclerosis are likely to go on to develop pulmonary arterial hypertension (PAH) and therefore benefit most from early treatment.
Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report.
United Therapeutics Corporation today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for Remodulin (treprostinil) Injection for the treatment of pulmonary arterial hypertension (PAH) by subcutaneous and intravenous administration.
The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from pulmonary hypertension.
Japanese patients respond well to pulmonary arterial hypertension-targeted drugs and may have a good prognosis with long-term survival, study findings suggest.
Researchers have identified a number of electrocardiography variables that progress between diagnosis and death in patients with pulmonary arterial hypertension.
The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology.
The world's leading voices in the fight against Pulmonary Hypertension have compiled a special publication detailing the breakthrough research into the causes of this debilitating vascular disease.
Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients, announced today that its investor group and employee shareholders have reached a definitive agreement to sell the Commercial Business to Madison Dearborn Partners in a transaction valued at approximately $1.6 billion.